CVRx Q4 2025 revenue $16.0M (+4% YoY); net loss $11.9M; FY2026 rev guidance $63-67M

CVRx, Inc.

2025-FY EPS reported -$2.04 vs consensus -$0.45 ▼ miss (-355.8%)

Q4 revenue $16.0M (US $14.9M, Europe $1.1M); gross margin 86% vs 83% YoY.
Net loss $11.9M ($0.46/sh) vs $10.7M ($0.43/sh) in Q4 2024; full year net loss $53.3M ($2.04/sh).
Active US implanting centers 252 (up 29 YoY); 53 US sales territories; BENEFIT-HF trial enrollment expected Q2 2026.
Jan 2026 amended debt facility: added $10M borrowing to $60M total, interest-only period extended, maturity May 2031.
FY2026 guidance: revenue $63-67M, gross margin 84-86%, op. expenses $103-107M; Q1 2026 revenue expected $13.7-14.7M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.